You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

List of Excipients in API semaglutide


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing semaglutide

Company Tradename Ingredient NDC Excipient Potential Generic Entry
Novo Nordisk OZEMPIC semaglutide 0169-4136 PHENOL 2031-12-05
Novo Nordisk OZEMPIC semaglutide 0169-4136 PROPYLENE GLYCOL 2031-12-05
Novo Nordisk OZEMPIC semaglutide 0169-4136 SODIUM PHOSPHATE, DIBASIC, DIHYDRATE 2031-12-05
Novo Nordisk OZEMPIC semaglutide 0169-4136 WATER 2031-12-05
Novo Nordisk WEGOVY semaglutide 0169-4525 SODIUM CHLORIDE 2031-12-05
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Detailed excipient profiles for semaglutide

Excipient focus: PHENOL

Excipient focus: PROPYLENE GLYCOL

Excipient focus: SODIUM CHLORIDE

Excipient focus: SODIUM PHOSPHATE, DIBASIC, DIHYDRATE

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.